Who is sponsoring NCT00639951?

NCT00639951 is sponsored by Instituto Bioclon S.A. de C.V..

What condition does NCT00639951 study?

NCT00639951 studies Snake Bite.

What drugs are being tested in NCT00639951?

Interventions: A, Antivipmyn ®.

What is the status of NCT00639951?

NCT00639951 is currently TERMINATED.

Last reviewed 2016-07-18 · How we verify

Multicentric, Randomized,Controlled and Comparative Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation

NCT00639951 Phase 4 TERMINATED

The purpose of this study is to compare whether a same total dose given up front as a single dose is more effective and as safe as the same dose given as a fractioned dose. Evaluate the Utility of the the Dry Tube Test Evaluating its Correlation with Coagulation Test Results (fibrinogen, platelets, INR, PT and PTT). Explore the Evolution of some Serum Markers (CK, DHL, metalloproteinase), Amount of Venom and Antivenom Levels and the Progression of Local Lesions.

Details

Lead sponsor	Instituto Bioclon S.A. de C.V.
Phase	Phase 4
Status	TERMINATED
Enrolment	10
Start date	2008-01
Completion	2009-03

Conditions

Snake Bite

Interventions

A
Antivipmyn ®

Primary outcomes

Resolution of systemic signs and symptoms of snake bite envenomation expressed as % of patients requiring additional antivenom and % of patients that are stable — 12 hours after initial treatment

Countries

Mexico